Searching across hundreds of databases
Batten disease is characterized by cognitive and motor impairment, retinal degeneration, and seizures leading to premature death. Recent studies have shown efficacy for a gene therapy approach for CLN7 Batten disease. This gene therapy approach is promising to treat cognitive and motor impairment, but is not likely to delay vision loss. Additionally, the natural progression of retinal degeneration in CLN7 Batten disease patients is not well-known.
Pubmed ID: 36374771 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets IgG
View all literature mentionsThis polyclonal targets RBPMS
View all literature mentionsThis polyclonal secondary targets IgG
View all literature mentionsThis monoclonal targets GAPDH antibody [GA1R]
View all literature mentionsThis unknown targets Prox1
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis unknown targets VGLUT1
View all literature mentionsThis recombinant monoclonal targets Iba1
View all literature mentionsThis monoclonal targets Glutamine Synthetase
View all literature mentionsThis unknown targets Opsin, Blue
View all literature mentionsThis monoclonal targets PRKCA
View all literature mentionsThis polyclonal targets Opsin Red/Green
View all literature mentionsThis recombinant monoclonal targets PSD95
View all literature mentionsThis monoclonal targets GFAP
View all literature mentionsThis polyclonal targets RBPMS
View all literature mentionsMus musculus with name C57BL/6J from IMSR.
View all literature mentionsThe SciCrunch Infrastructure was developed as a cooperative data platform to be used by diverse communities in making data more FAIR.
scicrunch.org
